Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGb 761 in Mild to Moderate Alzheimer's Disease
NCT00500500Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jul 2005
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing EGb 761 (Tanakan) with Placebo (2 arms). Primary endpoint: Effect of EGb 761 on the ratio of the isoform of the protein precursor of beta amyloid platelets. Started Jul 2005; status: terminated.
02
Drugs
ginkgo biloba extract
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00500500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500500.